Psoriasis is now considered to be the cutaneous phenotype of a systemic inflammatory
condition, recognized under the term Psoriatic Disease (PsD). PsD has several …

Introduction Generalized pustular psoriasis (GPP) is a rare form of psoriasis (less of 1% of
cases). Currently, GPP is recognized as a clinical entity, distinguished from plaque psoriasis …

Psoriasis is a chronic inflammatory cutaneous disease, affecting up to 3% of the worldwide
population. Several clinical phenotypes can be distinguished. Among these, erythrodermic …

Introduction Nowadays, despite the wide availability of biological drugs and apremilast for
psoriasis management, there is always a need for new therapies to customize the …

The management of patients affected by moderate-to-severe psoriasis may be challenging,
in particular in patients with serious infectious diseases [tuberculosis (TB), hepatitis B and C …

Erythroderma is a condition characterized by erythema affecting at least 90% of the skin
surface area. It can be caused by various underlying conditions. Due to nonspecific clinical …

Erythrodermic psoriasis (EP), a rare and severe subtype of psoriasis characterized by
prominent erythema affecting at least 80% of the body surface with a variety of systemic …

Background Erythrodermic psoriasis (EP) is a severe and rare condition characterized by
prominent erythema and scaling over 75% of the body surface area. Unlike psoriasis …

Psoriasis is an inflammatory skin disease largely driven by interleukin (IL)-17-producing T
helper 17 (Th17) cells and associated IL-17. 1 Secukinumab is a fully human …